Daejeon, South Korea

Mi Ae Jeon


 

Average Co-Inventor Count = 23.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Sure, I can help you with that! Here is an article about inventor Mi Ae Jeon:

Title: The Inventive Journey of Mi Ae Jeon

Introduction:

Mi Ae Jeon is a visionary inventor based in Daejeon, South Korea. His remarkable journey in the world of inventions is a testament to the power of creativity and perseverance. Jeon's impact on technology is profound, leaving a lasting legacy for future innovators to build upon.

Latest Patents:

Mi Ae Jeon holds an impressive 1 patent for his groundbreaking invention titled "Human antibody specific to c-Met and preparation method thereof." This patent introduces an antibody specifically bound to c-Met, isolated from a human Fv(ScFv) phage library. The fully human antibody demonstrates high affinity and specificity to c-Met, offering a novel approach to controlling c-Met activity in vivo.

Career Highlights:

Mi Ae Jeon is associated with Pharmabcine Inc., where he continues to push the boundaries of innovation in the field of biotechnology. His dedication to developing cutting-edge solutions has earned him recognition as a pioneer in the industry.

Collaborations:

Throughout his career, Mi Ae Jeon has collaborated with esteemed colleagues such as Jinsang Yoo and Ju Ryoung Nam. Together, they have worked tirelessly to advance scientific research and bring forth innovative products that have the potential to revolutionize healthcare.

Conclusion:

In conclusion, Mi Ae Jeon's passion for innovation and unwavering commitment to excellence have solidified his position as a leading inventor in the realm of biotechnology. His contributions have paved the way for future advancements in the field, inspiring generations to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…